UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934
Filed by the Registrant ☐
Filed by a Party other than the Registrant ☒
Check the appropriate box:
☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒ Definitive Proxy Statement
☐ Definitive Additional Materials
☐ Soliciting Material Under Rule 14a-12
BRISTOL-MYERS SQUIBB COMPANY (Name of Registrant as Specified in Its Charter)
STARBOARD VALUE LP
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD STARBOARD VALUE AND OPPORTUNITY MASTER FUND L LP
STARBOARD VALUE AND OPPORTUNITY S LLC STARBOARD VALUE AND OPPORTUNITY C LP
STARBOARD VALUE R LP
STARBOARD VALUE L LP STARBOARD VALUE R GP LLC STARBOARD LEADERS VICTOR LLC
STARBOARD LEADERS FUND LP
STARBOARD VALUE A LP STARBOARD VALUE A GP LLC STARBOARD VALUE GP LLC STARBOARD PRINCIPAL CO LP STARBOARD PRINCIPAL CO GP LLC
JEFFREY C. SMITH
PETER A. FELD
(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ No fee required.
☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) | Title of each class of securities to which transaction applies: |
(2) | Aggregate number of securities to which transaction applies: |
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is |
calculated and state how it was determined): | |
(4) | Proposed maximum aggregate value of transaction: |
(5) | Total fee paid: |
☐ | Fee paid previously with preliminary materials: |
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid |
previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
(1)Amount previously paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD
March 15, 2019
Dear Fellow Bristol-Myers Squibb Company Stockholders:
The attached proxy statement and the enclosed BLUE proxy card are being furnished to you, the stockholders of Bristol-Myers Squibb Company, a Delaware corporation ("Bristol-Myers" or the "Company"), in connection with the solicitation of proxies by Starboard Value and Opportunity Master Fund Ltd (together with its affiliates, "Starboard" or "we") to oppose the merger of Celgene Corporation ("Celgene") with a wholly-owned subsidiary of Bristol-Myers (the "Merger") at the special meeting of stockholders of Bristol-Myers to be held on April 12, 2019 (including any adjournments or postponements thereof, the "Special Meeting").
Pursuant to the terms of the merger agreement entered into by Bristol-Myers and Celgene on January 2, 2019 (the "Merger Agreement"), if the Merger is completed, Celgene stockholders immediately prior to the completion of the Merger will be entitled to receive $50.00 in cash, one share of Bristol-Myers Squibb common stock and one contingent value right (each, a "CVR") for each share of Celgene common stock held by them. The value of the consideration to be received by Celgene stockholders will fluctuate with changes in the price of the shares of Bristol-Myers common stock.
In order for the Merger to be completed and such merger consideration to be paid to Celgene stockholders, (i) Bristol-Myers stockholders must approve the issuance of shares of Bristol-Myers common stock in the Merger at the Special Meeting and (ii) Celgene stockholders must adopt the Merger Agreement at a separate special meeting of the stockholders of Celgene, also scheduled to be held on April 12, 2019.
We believe the Merger is ill-advised and not in the best interest of Bristol-Myers stockholders. Accordingly, pursuant to the attached proxy statement, we are soliciting proxies from holders of shares of Bristol-Myers stock to vote AGAINST the proposal being submitted at the Special Meeting for stockholders to approve the issuance of shares of Bristol-Myers common stock in connection with the Merger.
The Special Meeting is scheduled to be held on April 12, 2019 at the offices of Kirkland & Ellis LLP located at 601 Lexington Avenue, New York, New York 10022, at 10:00 a.m., Eastern Time.
We urge you to carefully consider the information contained in the attached proxy statement and then support our efforts by signing, dating and returning the enclosed BLUE proxy card today. The attached proxy statement and the enclosed BLUE proxy card are first being furnished to the stockholders on or about March 15, 2019.
If you have already voted for management's proposals relating to the Merger, you have every right to change your vote by signing, dating and returning a later dated proxy card.
If you have any questions or require any assistance with your vote, please contact Okapi Partners LLC, which is assisting us, at its address and toll-free numbers listed below.
Thank you for your support.
/s/ Jeffrey C. Smith
Jeffrey C. Smith
Starboard Value and Opportunity Master Fund Ltd
If you have any questions, require assistance in voting your BLUE proxy card, or need additional copies of Starboard's proxy materials, please contact Okapi Partners at the phone numbers or email address listed below.
Okapi Partners LLC
1212 Avenue of the Americas, 24 th Floor
New York, New York 10036
+ 1 (212) 297-0720 (Main) + 1 (888) 785-6617 (Toll-Free) Email:info@okapipartners.com
SPECIAL MEETING OF STOCKHOLDERS
OF
BRISTOL-MYERS SQUIBB COMPANY _________________________
PROXY STATEMENT
OF
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD _________________________
PLEASE SIGN, DATE AND MAIL THE ENCLOSED BLUE PROXY CARD TODAY
Starboard Value LP ("Starboard Value LP"), Starboard Value and Opportunity Master Fund Ltd ("Starboard V&O Fund"), Starboard Value and Opportunity S LLC ("Starboard S LLC"), Starboard Value and Opportunity C LP ("Starboard C LP"), Starboard Value and Opportunity Master Fund L LP ("Starboard L Master"), Starboard Value L LP ("Starboard L GP"), Starboard Leaders Victor LLC ("Starboard Victor LLC"), Starboard Leaders Fund LP ("Starboard Leaders Fund"), Starboard Value A LP ("Starboard A LP"), Starboard Value A GP LLC ("Starboard A GP"), Starboard Value GP LLC ("Starboard Value GP"), Starboard Principal Co LP ("Principal Co"), Starboard Principal Co GP LLC ("Principal GP"), Starboard Value R LP ("Starboard R LP"), Starboard Value R GP LLC ("Starboard R GP"), Jeffrey C. Smith and Peter A. Feld (collectively, "Starboard" or "we") are stockholders of Bristol-Myers Squibb Company, a Delaware corporation ("Bristol-Myers" or the "Company"), who beneficially own in the aggregate 4,430,000 shares of common stock, $0.10 par value per share (the "Common Stock"), of the Company.
We are writing to you in connection with the proposed acquisition of Celgene Corporation ("Celgene") by Bristol-Myers (the "Merger"). In connection with the proposed Merger, Bristol-Myers entered into an Agreement and Plan of Merger, dated as of on January 2, 2019, with Celgene and Burgundy Merger Sub, Inc., a wholly-owned subsidiary of Bristol-Myers (the "Merger Agreement"). The Board of Directors of Bristol-Myers (the "Board") has scheduled a special meeting of stockholders for the purpose of considering and voting on certain proposals relating to the proposed Merger (including any adjournments or postponements thereof, the "Special Meeting"). The Special Meeting is scheduled to be held on April 12, 2019 at the offices of Kirkland & Ellis LLP located at 601 Lexington Avenue, New York, New York 10022, at 10:00 a.m., Eastern Time.
Pursuant to this Proxy Statement, Starboard is soliciting proxies from holders of the Common Stock and holders of the $2.00 convertible preferred stock, $1.00 par value per share (the "Preferred Stock" and together with the Common Stock, the "Bristol-Myers Stock"), in respect of the following proposals to be considered at the Special Meeting, each as described in greater detail in the proxy statement/prospectus of Bristol-Myers on Form 424B3, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2019 (the "Bristol-Myers Merger Proxy Statement") for the Special Meeting (such proposals, the "Bristol-Myers Merger Proposals"):
1. The Company's proposal to approve the issuance of shares of Bristol-Myers Common Stock in the Merger as contemplated by the Merger Agreement (the "Stock Issuance Proposal"); and
2. The Company's proposal to approve the adjournment from time to time of the Special Meeting, if necessary to solicit additional proxies if there are not sufficient votes at the time of Special Meeting to approve the Stock Issuance Proposal (the "Adjournment Proposal").
Attachments
- Original document
- Permalink
Disclaimer
Bristol-Myers Squibb Company published this content on 15 March 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 March 2019 16:48:08 UTC